These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 11081183

  • 1. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E.
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [Abstract] [Full Text] [Related]

  • 2. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [Abstract] [Full Text] [Related]

  • 3. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 4. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [Abstract] [Full Text] [Related]

  • 5. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E, Maccagno B, Ramunni J, Gianotti L, Di Vito L, Deghenghi R, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [Abstract] [Full Text] [Related]

  • 6. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
    Arvat E, Ramunni J, Bellone J, Di Vito L, Baffoni C, Broglio F, Deghenghi R, Bartolotta E, Ghigo E.
    Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
    [Abstract] [Full Text] [Related]

  • 7. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [Abstract] [Full Text] [Related]

  • 8. The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.
    Bartolotta E, Bellone J, Aimaretti G, Arvat E, Benso L, Deghenghi R, Camanni F, Ghigo E.
    J Pediatr Endocrinol Metab; 1997 Nov; 10(5):491-7. PubMed ID: 9401905
    [Abstract] [Full Text] [Related]

  • 9. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.
    Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F.
    Eur J Endocrinol; 1996 Oct; 135(4):407-12. PubMed ID: 8921821
    [Abstract] [Full Text] [Related]

  • 10. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E.
    Peptides; 1997 Oct; 18(6):885-91. PubMed ID: 9285939
    [Abstract] [Full Text] [Related]

  • 11. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 Oct; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 12. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 13. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.
    Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, Mucci M, Boghen MF, Camanni F.
    J Endocrinol Invest; 1994 Mar; 17(3):157-62. PubMed ID: 8051337
    [Abstract] [Full Text] [Related]

  • 14. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [Abstract] [Full Text] [Related]

  • 15. Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women.
    Arvat E, Gianotti L, Broglio F, Maccagno B, Bertagna A, Deghenghi R, Camanni F, Ghigo E.
    Eur J Endocrinol; 1997 May; 136(5):483-7. PubMed ID: 9186268
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
    Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, Camanni F, Ghigo E.
    Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975
    [Abstract] [Full Text] [Related]

  • 17. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.
    Grottoli S, Maccario M, Procopio M, Oleandri SE, Arvat E, Gianotti L, Deghenghi R, Camanni F, Ghigo E.
    Eur J Endocrinol; 1996 Dec; 135(6):678-82. PubMed ID: 9025712
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G, Grugni G, Morabito F.
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [Abstract] [Full Text] [Related]

  • 19. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.
    Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Cocchi D, Müller EE, Camanni F.
    J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330
    [Abstract] [Full Text] [Related]

  • 20. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E, Gianotti L, Ragusa L, Valetto MR, Cappa M, Aimaretti G, Ramunni J, Grottoli S, Camanni F, Ghigo E.
    Dementia; 1996 Feb; 7(5):288-92. PubMed ID: 8872421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.